Abstract
Introduction: The prodromal Alzheimers disease (AD) is a new concept that include an amnesic mild cognitive impairment (MCI- a) and alterations in some complementary tests. Objective: To test the presence of alterations in the cerebrospinal fluid (CSF) bio- markers in our MCI-a patients who developed AD in the first year after the lumbar puncture. Method: 24 control subjects and 36 MCI-a patients were included from the local hospital memory cli- nic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we quantified CSF Aβ1-42, T-tau and P-tau181p proteins, and calcu- lated the ratios T-tau / Aβ1-42 y P-tau 181p / Aβ1-42. This project was approved by the local Ethical Committee. Results: One year after the lumbar puncture, 14 MCI patients (38%) developed AD. These patients showed lower Aβ1-42 protein levels (285.37 ± 73.36 vs. 365.21 ± 112.53 pg/ml, p < 0.02) and higher T-tau protein (88.3 ± 40.82 vs. 53.21 ± 23.38 pg/ml, p < 0.002), P-tau 181p protein (66.44 ± 23.87 vs. 31.25 ± 13.74 pg/ml, p< 0.02 ), T-tau / Aβ1-42 ratio (0.34 ± 0.19 vs. 0.15 ± 0.08, p < 0.001 ) and P-tau 181p / Aβ1-42 ratio (0.25 ± 0.12 vs. 0.09 ± 0.06, p < 0.0001) than the control subjects. Conclusion: In our experience, as the recent literature, it exist the very clear alterations of CSF biomarkers in patients with prodromal AD. (Alzheimer. Real Invest Demenc. 2011;49:19-25)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
